Naturally processed and concealed HLA-A2.1-Restricted epitopes from tumor-associated antigen tyrosinase-related protein-2

International Journal of Cancer

Volumn 87, Issue 2, 2000, Pages 241-246

  Noppen, Christoph ^a,c   Lévy, Frédéric ^b   Burri, Lena ^b   Zajac, Paul ^a   Remmeil, Eugenia ^a   Schaefer, Christoph ^a   Lüscher, Urs ^a   Heberer, Michael ^a   Spagnoli, Giulio C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Research Division Lab 401   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 2;

AMINO TERMINAL SEQUENCE; ANTIGEN PRESENTATION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXICITY TEST; GENE EXPRESSION; HLA MATCHING; HLA SYSTEM; HUMAN; HUMAN CELL; MELANOMA CELL; MOLECULAR CLONING; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ACETYLCYSTEINE; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; COCULTURE TECHNIQUES; CYSTEINE PROTEINASE INHIBITORS; DNA MUTATIONAL ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HIV PROTEASE INHIBITORS; HLA-A2 ANTIGEN; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LEUKOCYTES, MONONUCLEAR; MELANOMA; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RITONAVIR; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0342647351     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000715)87:2<241::AID-IJC15>3.0.CO;2-L     Document Type: Article

References (32)

1. ADAMS, J., PALOMBELLA, V.J., SAUSVILLE, E.A., JOHNSON, J., DESTREE, A., LAZARUS, D.D., MAAS, J., PIEN, C.S., PRAKASH, S. and ELLIOTI, P.J., Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res., 59, 2615-2622 (1999).
2. ANDRE, P., GROETTRUP, M., KLENERMAN, P., DE GIULI, R., BOOTH, B.L.J., CERUNDOLO, V., BONNEVILLE, M., JOTEREAU, F., ZINKERNAGEL, R.M., and LOTTEAU, V., An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. nat. Acad. Sci. (Wash.), 95, 13120-13124 (1998).
3. BOON, T., GAJEWSKI, T.F., and COULIE, P.G., From defined human tumor antigens to effective immunization? Immunol. Today, 16, 334-336 (1995).
4. CASTELLI, C., TARSINI, P., MAZZOCCHI, A., RINI, F., RIVOLTINI, L., RAVAGNANI, F., GALLINO, F., BELLI, F., and PARMIANI, G., Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp 100 melanoma antigens. J. Immunol., 162, 1739-1748 (1999).
5. CHEN, Y.T., STOCKERT, E., JUNGBLUTH, A., TSANG, S., COPLAN, K.A., SCANLAN, M.J., and OLD, L.J., Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc. nat. Acad. Sci. (Wash.), 93, 5915-5919 (1996).
6. CHEN, Y.T., STOCKERT, E., TSANG, S., COPLAN, K.A., and OLD, L.J., Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc. nat. Acad Sci. (Wash.), 92, 8125-8129 (1995).
7. D'AMARO, J., HOUBIERS, J.G., DRIJFHOUT, J.W., BRANDT, R.M., SCHIPPER, R., BAVINCK, J.N., MELIEF, C.J., and KAST, W.M., A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. Hum. Immunol., 43, 13-18 (1995).
8. JÄGER, E., RINGHOFFER, M., ALTMANNSBERGER, M., ARAND, M., KARBACH, J., JAGER, D., OESCH, F., and KNUTH, A., Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer, 71, 142-147 (1997).
9. JURETIC, A., JÜRGENS-GÖBEL, J., SCHAEFER, C., NOPPEN, C., WILLIMANN, T.E., KOCHER, T., ZUBER, M., HARDER, F., HEBERER, M., and SPAGNOLI, G.C., Cytotoxic T-lymphocyte responses against mutated p21 ras peptides: an analysis of specific T-cell-receptor gene usage. Int. J. Cancer, 68, 471-478 (1996).
10. LACKEY, C.J., KING, G.M., MARTO, J.A., VENKETESWARAN, S., MAIER, B.F., CROTZER, V.L., COLELLA, T.A., SHABANOWITZ, J., HUNT, D.F., and ENGELHARD, V.H. Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol. J. Immunol., 161, 112-121 (1998).
11. MAEURER, M.J., STORKUS, W.J., KIRKWOOD, J.M., and LOTZE, M.T., New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res., 6, 11-24 (1996).
12. MARTI, W.R., ZAJAC, P., SPAGNOLI, G., HEBERER, M., and OERTLI, D., Nonreplicating recombinant vaccinia virus encoding human B-7 molecules elicits effective costimulation of naive and memory CD4+ T lymphocytes in vitro. Cell. Immunol., 179, 146-152 (1997).
13. NESTLE, F.O., ALIJAGIC, S., GILLIET, M., SUN, Y., GRABBE, S., DUMMER, R., BURG, G., and SCHADENDORF, D., Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature (Med.), 4, 328-332 (1998).
14. NOPPEN, C., SPAGNOLI, G.C., and SCHAFEER, C., Isolation of multiple mRNAs from a few eukaryotic cells: a fast method to obtain templates for RT-PCR. Biotechniques, 21, 394-396 (1996).
15. NUSSBAUM, A.K., DICK, T.P., KEILHOLZ, W., SCHIRLE, M., STEVANOVIC, S., DIETZ, K., HEINEMEYER, W., GROLL, M., WOLF, D.H., HUBER, R., RAMMENSEE, H.G., and SCHILD, H., Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc. nat. Acad. Sci. (Wash.). 95, 12504-12509 (1998).
16. OSSENDORP, F., EGGERS, M., NEISIG, A., RUPPERT, T., GROETTRUP, M., SIJTS, A., MENGEDE, E., KLOETZEL, P.M., NEEFJES, J., KOSZINOWSKI, U., and MELIEF, C., A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity. 5, 115-124 (1996).
17. PARKHURST, M.R., FITZGERALD, E.B., SOUTHWOOD, S., SETTE, A., ROSENBERG, S.A., and KAWAKAMI, Y., Identification of a shared HLA-A*0201-restricled T-cell epitope from the melanoma antigen tyrosinase-related protein-2 (TRP-2). Cancer Res., 58, 4895-4901 (1998).
18. RAMMENSEE, H.G., Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol., 7, 85-96 (1995).
19. ROSENBERG, S.A., and 15 OTHERS, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature (Med.), 4, 321-327 (1998).
20. SALAZAR-ONFRAY, F., NAKAZAWA, T., CHHAJLANI, V., PETERSSON, M., KARRE, K., MASUCCI, G., CELIS, E., SETTE, A., SOUTHWOOD, S., APPELLA, E., and KIESSLING, R., Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res., 57, 4348-4355 (1997).
21. SKIPPER, J.C., HENDRICKSON, R.C., GULDEN, P.H., BRICHARD, V., VAN PEL, A., CHEN, Y., SHABANOWITZ, J., WÖLFEL, T., SLINGLUFF, C.L.J., BOON, T., HUNT, D.F., and ENGELHARD, V.H., An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. exp. Med., 183, 527-534 (1996).
22. SPAGNOLI, G.C., SCHAEFER, C., WILLIMANN, T.E., KOCHER, T., AMOROSO, A., JURETIC, A., ZUBER, M., LÜSCHER, U., HARDER, F., and HEBERER, M., Peptide-specitic CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int. J. Cancer, 64, 309-315 (1995).
23. STOLTZE, L., DICK, T.P., DEEG, M., POMMERL, B., RAMMENSEE, H.G., and SCHILD, H., Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and -independent proteolytic activities. Europ. J. Immunol., 28, 4029-4036 (1998).
24. THEOBALD, M., and 12 OTHERS, The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J. exp. Med., 188, 1017-1028 (1998).
25. TSAI, V., SOUTHWOOD, S., SIDNEY, J., SAKAGUCHI, K., KAWAKAMI, Y., APPELLA, E., SETTE, A., and CELIS, E., Identification of subdominant CTL, epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol., 158, 1796-1802 (1997).
26. VALMORI, D., FONTENEAU, J.F., LIZANA, C.M., GERVOIS, N., LIENARD, D., RIMOLDI, D., JONGENEEL, V., JOTEREAU, F., CEROTTINI, J.C., and ROMERO, P., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominanl peptide analogues. J. Immunol., 160, 1750-1758 (1998).
27. VALMORI, D., GILEADI, U., SERVIS, C., DUNBAR, P.R., CEROTTINI, J.C., ROMERO, P., CERUNDOLO, V., and LÉVY, F., Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. exp. Med., 189, 895-906 (1999).
28. VONDERHEIDE, R.H., HAHN, W.C., SCHULTZE, J.L., and NADLER, L.M., The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity, 10, 673-679 (1999).
29. WANG, R.F., APPELLA, E., KAWAKAMI, Y., KANG, X., and ROSENBERG, S.A., Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. exp. Med. 184, 2207-2216 (1996).
30. WANG, R.F., JOHNSTON, S.L., SOUTHWOOD, S., SETTE, A., and ROSENBERG, S.A., Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J. Immunol., 160, 890-897 (1998).
31. YELLEN-SHAW, A.J., WHERRY, E.J., DUBOIS, G.C., and EISENLOHR, L.C., Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J. Immunol., 158, 3227-3234 (1997).
32. ZAJAC, P., SCHÜTZ, A., OERTLI, D., NOPPEN, C., SCHAEFER, C., HEBERER, M., SPAGNOLI, G.C., and MARTI, W.R., Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules. Cancer Res., 58, 4567-4571 (1998).